Population Pharmacokinetics of Fasinumab in Healthy Volunteers and Patients With Pain Due to Osteoarthritis of the Knee or Hip
Clinical Pharmacology in Drug Development · 2024
DOI: 10.1002/cpdd.1380 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Kuan-Ju Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. Hauptthemen laut MEDLINE: Osteoarthritis, Knee, Healthy Volunteers, Osteoarthritis, Hip, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Osteoarthritis (OA) pain management options are currently limited. Fasinumab, an anti‐nerve growth factor monoclonal antibody, has been investigated in healthy volunteers and patients with OA‐related pain, among other conditions. Data from 12 Phase I‐III clinical trials of 92 healthy volunteers and 7430 patients with OA were used to develop a population pharmacokinetic model to characterize fasinumab concentration‐time profiles and assess the covariates’ effect on fasinumab pharmacokinetic parameters. Participants received single or repeated fasinumab doses intravenously (IV)/subcutaneously (SC), based on body weight (0.03‐1 mg/kg IV or 0.1‐0.3 mg/kg SC)/fixed dose (9‐12 mg IV or 1‐12 mg SC). Fasinumab concentration‐time data following IV and SC administration in healthy volunteers and patients with OA‐related pain were adequately described by a 2‐compartment model. Bioavailability increased with higher doses; estimated at 55.1% with 1 mg SC dose, increasing in a greater‐than‐proportional manner above this. Body weight had the largest predicted impact on fasinumab steady‐state exposures, participants at the 5th and 95th percentiles had a 43%‐45% higher/22%‐23% lower exposure versus reference, respectively. Other covariates had small but clinically irrelevant impacts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Zitieren
APA
Lin, K. J., Turner, K. C., Hassan, H. E., Harnisch, L. O., Davis, J. D., & DiCioccio, A. T. (2024). Population Pharmacokinetics of Fasinumab in Healthy Volunteers and Patients With Pain Due to Osteoarthritis of the Knee or Hip. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1380
Vancouver
Lin KJ, Turner KC, Hassan HE, Harnisch LO, Davis JD, DiCioccio AT. Population Pharmacokinetics of Fasinumab in Healthy Volunteers and Patients With Pain Due to Osteoarthritis of the Knee or Hip. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1380
BibTeX
@article{Lin2024,
author = {Lin, Kuan-Ju and Turner, Kenneth C and Hassan, Hazem E and Harnisch, Lutz O and Davis, John D and DiCioccio, Albert Thomas},
title = {Population Pharmacokinetics of Fasinumab in Healthy Volunteers and Patients With Pain Due to Osteoarthritis of the Knee or Hip},
journal = {Clinical Pharmacology in Drug Development},
year = {2024},
doi = {10.1002/cpdd.1380}
}
EUVIMED